Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $11

Benzinga Newsdesk www.benzinga.com Positive 88.3%

Neg 0% Neu 0% Pos 88.3%

Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ:ALLR) with a Buy and raises the price target from $10.25 to $11.